Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature
Authors
Keywords
-
Journal
Infectious Diseases
Volume 50, Issue 5, Pages 381-387
Publisher
Informa UK Limited
Online
2017-12-19
DOI
10.1080/23744235.2017.1390248
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epstein-Barr virus gastric ulcer associated with ruxolitinib
- (2016) Yoshiharu Kusano et al. ANNALS OF HEMATOLOGY
- Klebsiella pneumoniae primary liver abscess associated with ruxolitinib
- (2016) Yoshiharu Kusano et al. ANNALS OF HEMATOLOGY
- Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib
- (2016) Benoit Branco et al. ANNALS OF HEMATOLOGY
- Elevation of the Hepatitis B Virus DNA during the Treatment of Polycythemia Vera with the JAK Kinase Inhibitor Ruxolitinib
- (2016) Keita Kirito et al. INTERNAL MEDICINE
- Case of disseminated molluscum contagiosum caused by ruxolitinib, a Janus kinase 1 and 2 inhibitor
- (2016) Manao Kinoshita et al. JOURNAL OF DERMATOLOGY
- Cytomegalovirus Retinitis in a Patient Who Received Ruxolitinib
- (2016) Joanna von Hofsten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib
- (2015) Chih-Cheng Chen et al. ANNALS OF HEMATOLOGY
- JAK1/2 inhibition impairs T cell functionin vitroand in patients with myeloproliferative neoplasms
- (2015) Sowmya Parampalli Yajnanarayana et al. BRITISH JOURNAL OF HAEMATOLOGY
- JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
- (2015) Kathrin Schönberg et al. CANCER RESEARCH
- A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- (2015) Naveen Pemmaraju et al. Clinical Lymphoma Myeloma & Leukemia
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological Consequences of JAK Inhibition: Friend or Foe?
- (2015) Donal P. McLornan et al. Current Hematologic Malignancy Reports
- Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge
- (2014) Francesca Palandri et al. ANNALS OF HEMATOLOGY
- Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts
- (2014) F. Passamonti et al. BLOOD
- Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment
- (2014) Lana X. Tong et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Disseminated tuberculosis associated with ruxolitinib
- (2014) R K Hopman et al. LEUKEMIA
- Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis
- (2014) Yen-Hao Chen et al. LEUKEMIA & LYMPHOMA
- Hepatitis B virus reactivation associated with ruxolitinib
- (2013) Chien-Heng Shen et al. ANNALS OF HEMATOLOGY
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
- (2013) F. Cervantes et al. BLOOD
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
- (2013) A. Heine et al. BLOOD
- Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
- (2013) A. Heine et al. BLOOD
- An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor
- (2013) Nicholas G. Wysham et al. CHEST
- Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
- (2013) S. Verstovsek et al. HAEMATOLOGICA
- Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2013) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
- (2013) G Caocci et al. LEUKEMIA
- Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
- (2013) Rowan Wathes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bilateral Toxoplasmosis Retinitis Associated with Ruxolitinib
- (2013) Roger A. Goldberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ruxolitinib can mask symptoms and signs of necrotizing fasciitis
- (2012) G.W.D. Landman et al. JOURNAL OF INFECTION
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More